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Sudorimetry technology has evolved dramatically, as a rapid, non-invasive, robust, and
accurate biomarker for small fibers that can easily be integrated into clinical practice.
Though skin biopsy with quantitation of intraepidermal nerve fiber density is still currently
recognized as the gold standard, sudorimetry may yield diagnostic information not only
on autonomic dysfunction but also enhance the assessment of the small somatosensory
nerves, disease detection, progression, and response to therapy. Sudorimetry can be
assessed using Sudoscan™, which measures electrochemical skin conductance (ESC)
of hands and feet. It is based on different electrochemical principles (reverse iontophore-
sis and chronoamperometry) to measure sudomotor function than prior technologies,
affording it a much more practical and precise performance profile for routine clinical
use with potential as a research tool. Small nerve fiber dysfunction has been found to
occur early in metabolic syndrome and diabetes and may also be the only neurological
manifestation in small fiber neuropathies, beneath the detection limits of traditional nerve
function tests. Test results are robust, accomplished within minutes, require little technical
training and no calculations, since established norms have been provided for the effects
of age, gender, and ethnicity. Sudomotor testing has been greatly under-utilized in the
past, restricted to specialized centers capable of handling the technically demanding
and expensive technology. Yet, evaluation of autonomic and somatic nerve function
has been shown to be one of the best estimates of cardiovascular risk. Evaluation of
sweating has the appeal of quantifiable non-invasive determination of the integrity of the
peripheral autonomic nervous system, and can now be accomplished rapidly at point of
care clinics with the determination of ESC, allowing intervention for morbid complications
prior to permanent structural nerve damage. We review here sudomotor function testing
technology, the research evidence accumulated supporting the clinical utility of measuring
ESC, the medical applications of sudorimetry now available to physicians with this device,
and clinical vignettes illustrating its use in the clinical decision-making process.
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Evaluation of autonomic and somatic nerve function has now
been shown to be one of the most important predictors of cardio-
vascular risk (1–6). While there are bedside means of evaluation
of the integrity of the somatic nervous system (NIS-LL (7, 8),
UENS (9), and MNSI (10), these are imprecise and the use of
gold standard measures such as nerve conduction studies are
burdensome, time consuming, and do not capture small nerve
fiber function (11–13). Clearly a simple, rapid, and precise means
of quantification of both large and small fiber function would
greatly enhance the capacity to capture all the elements of periph-
eral and autonomic neuropathy. Autonomic function tests have
been extraordinarily useful in diagnosing, treating, and better
understanding of the complex mechanisms behind disturbances
in balance of the function of the two domains of the autonomic
nervous system, namely sympathetic and parasympathetic (14).
The ability to capture time and frequency domains of heart rate
variability (14), as well as baroreceptor sensitivity, has facilitated
the evaluation of balance between the two arms of the autonomic
nervous system, providing information on functional changes
prior to the development of permanent structural damage and
allowing the use of rebalancing therapeutic options (15). Small
unmyelinated C and Aδ fibers in the periphery subserve somatic
and autonomic nerve functions such as warm, cold, and pain
perception, as well as innervating sweat glands. The gold standard
for their evaluation has been skin biopsy and quantification of
intraepidermal nerve fiber density, an invasive procedure (16, 17).
On the other hand, the evaluation of sweating has the appeal of
quantifiable non-invasive determination of the integrity of the
peripheral autonomic nervous system. However, activation of
sweat glands is complex and both sympathetic and parasympa-
thetic innervation contribute to normal sweat gland function (18).
A variety of techniques have capitalized on quantifying sweating
(19) or the innervation of sweat glands (20, 21) to capture the
impact of disordered regulation on structure and function of sweat
glands as surrogates for the underlying somatic and autonomic
dysfunction.
Sudorimetry – or sudomotor function testing – the sci-
ence of measuring the function of sweat gland innervation, is
unique among the autonomic function tests in that it evalu-
ates the peripheral sympathetic system but relies principally on
cholinergic post-ganglionic neurotransmission. Recently, a newer
sudomotor function technology (Sudoscan) has become available
and adds a new tool to test at point of care in the clinic when
autonomic testing had been previously restricted to specialized
neurological laboratories. With an aging, increasingly obese pop-
ulation with diabetes and prediabetes, disorders that manifest
autonomic dysfunctions are becoming common and sudorimetry
may allow earlier intervention for these morbid complications.
Sudomotor Function Technology: The Why
and the How
Sweat glands being present at the skin surface, their stimulation
and measured response have been extensively utilized to assess
disorders of the autonomic system non-invasively, specifically
the peripheral sympathetic system. Sudomotor nerves are C-
fibers, thin unmyelinated, or poorly myelinated with primarily
cholinergic neurotransmission, wherein the neurotransmitter at
the ganglion is acetylcholine, the principal neurotransmitter of the
parasympathetic nervous system. However, epinephrine, nore-
pinephrine, vasoactive intestinal peptide (VIP), atrial natriuretic
peptide, calcitonin gene related polypeptide (CGRP), galanin,
ATP, and substance P have also been localized to peri-glandular
nerves (22). The nerve fibers are structurally similar to small nerve
fibers of warm and cold thermal perception, and hence prone to
damage by the same metabolic insults (Figure 1).
Small nerve fiber dysfunction has been found to occur early in
metabolic syndrome and diabetes (23, 24), and may also be the
only neurological manifestation in small fiber neuropathies (25,
26). Apart from skin biopsy, measuring small nerve fiber function
has been limited to assessment of symptoms and quantitative
sensory testing for warm, cold, and pain thresholds, which lack
the precision required for a practical clinical profile or use in the
research arena.
The unique qualities of sudomotor function tests are that, in
clinical application, they may yield diagnostic information not
only of autonomic dysfunction but also enhance the assessment
of the small somatosensory nerves (27, 28). To date, however,
most sudomotor function testing procedures were not accessible
for widespread use but rather confined to specialized autonomic
FIGURE 1 | Fibers of the peripheral nervous system: note the afferent and efferent connections among the small Aδ and C fibers (71).
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labs. Tests using iodine and starch (thermoregulatory sweat test),
the Neuropad (29, 30), or iontophoretic stimulation and quantifi-
cation of sweating are either time consuming, technically demand-
ing, or lack sensitivity, specificity, or reproducibility to be of
practical use (31–33). Furthermore, they were prone to both envi-
ronmental and patient-specific confounders like room temper-
ature, medications, food, and habituation. Excellent reviews on
sudomotor function tests can be read elsewhere (19).
In contrast, Sudoscan™ is based on different electrochemical
principles (reverse iontophoresis and chronoamperometry) to
measure sudomotor function than prior technologies, affording it
amuchmore practical and precise performance profile for routine
clinical use with potential as a research tool. The device consists of
a simple desktop computer connected to two sets of large surface
stainless steel electrodes: two for application of the palms, and
two for the soles. The patient places both hands and feet simul-
taneously on the designated electrodes and a painless scanning
process ensues over the course of 2–3min. A low DC voltage is
incrementally applied to the electrodes, ranging from 1 to 4V,
with the left and right electrodes serving alternatively as cathode
and anode. At voltages under 10V, the thick stratum corneum
is electrically insulating; the sweat glands, however, consist of
a cellular bilayer and therefore can transmit electrically charged
ions to the skin surface and the electrodes (reverse iontophoresis).
The current of sweat chloride ions generated in response to the
incremental voltage applied can be quantified and reflects the
function of the sweat gland, and hence its C fiber innervation.
This chloride ion current is reported as electrochemical skin
conductance (ESC) – the inverse of resistance – measured in
microSiemens (µS).
The palms and soles are specifically assessed due to their very
high density of sweat glands and the frequency of small nerve
degeneration occurring in a length-dependent fashion; i.e., affect-
ing the distal-most nerve endings first. Also, by alternating the
left and right extremities as anode and cathode, each extremity
is evaluated separately during the 3min scan, and asymmetry
between the extremities can be calculated by the device.
Clinical Diagnostic Evaluation Using ESC:
Assessment of Somatic and Autonomic
Nerve Dysfunction
The clinical diagnostic accuracy of Sudoscan™ has been evalu-
ated for diabetic peripheral sensorimotor polyneuropathy (DPN),
peripheral small fiber neuropathy, and autonomic neuropathy
against other standard methods.
Casellini et al. (34) examined 83 type 1 and 2 diabetic patients,
both with and without DPN, and compared them to 210 healthy
controls (HC).Diabetic patients withDPNhad significantly worse
ESCs of both feet and hands than patients without DPN and HC
[56.3 3 vs. 75.9 5.5 and 84.4 0.9 (p< 0.0001) for feet and
51.9 2.4 vs. 67.5 4.3 and 73.1 0.8 (p< 0.0001) for hands].
Somewhat surprisingly, ESCs correlated significantly with clinical
neuropathy scores of sensory, motor, and reflex function; somatic
(quantitative sensory testing and nerve conduction studies) and
autonomic (quantitative autonomic function testing) measures
of DPN suggesting that the measure captures both somatic and
FIGURE 2 | Electrochemical skin conductance of feet
receiver–operator characteristic (ROC) curve to reflect diabetic
neuropathy. Area under the curve= 0.8755, p<0.0001 (34).
autonomic nerve function. Using a Neuropathy Impairment Score
of the Lower Limb (NIS-LL) >2 as the gold standard for the
diagnosis of neuropathy, the sensitivity and specificity of ESC
for the diagnosis of DPN were 78 and 92%, respectively, for
feet, with an ROC area under the curve of 0.8755 (p< 0.0001)
(Figure 2). Table 1 compares ESC results to vibration detection
threshold (VDT) and sural amplitude and suggests that Sudoscan
is a moderately sensitive but highly specific tool to detect DPN.
The investigators further determined the correlations between
sudorimetry and somatic and autonomic function as shown in 48
type 2 diabetic patients (Table 2). There were strong correlations
between ESC and both somatic (sensory and motor) and auto-
nomic functions; sudorimetry scores were also able to separate
painful from non-painful DPN.
In this cohort, sweat gland size and morphology were not
available. There is evidence that sweat glands and sweat gland duct
diameter may be smaller in patients with DPN (35, 36); one likely
etiology is the thickened endothelial basement membranes of
feeding capillaries resulting inmicrovascular damage of cutaneous
structures. However, the contribution of these morphological
abnormalities to diabetic sudomotor dysfunction is not known.
Distal symmetric polyneuropathy (DSP) presents with small
fiber-predominant dysfunction; early detection currently relies on
skin biopsy with quantification of intraepidermal nerve fiber den-
sity (IENFD). Smith et al. (9) studied 55 patients with suspected
DSP (idiopathic or diabetes-related) and 42 HC to evaluate the
diagnostic performance of ESC. Using an abnormal Utah Early
Neuropathy Score (UENS) 4 as the diagnostic gold standard,
feet and hands ESC were significantly lower in DSP subjects than
HC, regardless of the etiology of DSP: 64 22 vs. 76 14µS,
and 58 19 vs. 66 18µS, respectively. More importantly, ESC
and IENFD had similar diagnostic performance in detecting DSP,
with a ROC area under the curve of 0.761 and 0.752, respectively
(Figure 3).Mirroring the findings of Casellini et al., feet ESC had a
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TABLE 1 | Diagnostic efficiency of feet and hands electrochemical skin conductance to reflect diabetic neuropathy (Neurologic Impairment Score – lower
limbs) (34).
Criteriona Sensitivity Specificity +LR  LR +PV  PV
Hands ESC 64 78.33 85.71 5.48 0.25 61.04 93.26
Feet ESC 77 78.34 92.38 10.28 0.23 74.6 93.72
Total NIS-LL 1.5 76.67 85.71 5.37 0.27 95.83 46.15
aCriterion corresponding with highest Youden index.
ESC, electrochemical skin conductance;+LR, positive likelihood ratio; LR, negative likelihood ratio; NIS–LL, Neurologic Impairment Score–Lower Legs;+PV, positive predictive value;
 PV, negative predictive value.
very high negative predictive value (83%) and significantly corre-
lated with both symptoms and signs assessed using the Michigan
Neuropathy Screening Instrument (MNSI) and the Utah early
neuropathy symptom scale(UENS). Also, quantitative sudomo-
tor axon reflex testing (QSART) at the foot and feet ESC were
correlated, but only moderately (0.348, p< 0.015); the authors
attributed this observation to the large standard deviation in the
QSART data, a reflection of variability in sweat volume produced.
An alternate explanation is that Cl ion transport may reflect
functions other than sweating alone (9).
Yajnik and colleagues (37) investigated DPN and autonomic
neuropathy in 265 type 2 diabetic patients using ESC measure-
ments, MNSI, and vibration perception threshold (VPT). Again,
feet ESC were significantly correlated with MNSI Part A (symp-
toms, p< 0.05) and Part B (physical examination, p< 0.001),
and VPT (p< 0.001). Gin et al. (38) similarly compared ESC to
VPT in the diagnosis of DPN among 142 diabetic (67% type 2)
individuals. The correlation coefficient between foot ESC and
VPT was  0.45 (p< 0.0001). VPT and ESC also correlated with
retinopathy status [r= 0.52 (SD0.07) and 0.52 (SD0.07), respec-
tively; p< 0.0001] and with creatinine clearance (p= 0.003) in the
Modification of Diet in Renal Disease (MDRD).
As in the study by Casellini and collaborators, a number of
projects have shown that ESC measurement may be a simple tool
for early identification of autonomic neuropathy, and may be
useful in screening for sub-clinical cardiac autonomic neuropathy
(CAN). Calvet et al. (39) in 232 diabetic individuals showed a high
correlation between CAN risk score (calculated from ESC) and
the low frequency (LF) component, a measure of sympathetic and
baroreceptor function (40), during moderate activity (r= 0.47,
p< 0.001). When taking the LF power component during mod-
erate activity <90ms2 as a reference value, the ROC area under
the curve for the CAN risk score was 0.77, with a sensitivity and
specificity of 83 and 63%, respectively.
Below are summarized some of the major studies completed
using ESCmeasurement in a clinical diagnostic capacity (Table 3).
Validation of ESC Robustness
For ESCmeasurement to be clinically meaningful, widely applica-
ble thresholds for normal and abnormal sudomotor function had
to be determined, and high reproducibility of results had to be
demonstrated. One of the weaknesses of many sudomotor func-
tion tests has been their wide range of normal values (QSART)
and their sensitivity to temperature, age, medications, and food.
Habituation (decreases in result amplitude with repeated testing)
is a particular problem with sympathetic skin response.
Initially, a large cohort of healthy subjects (432 females,
177 males; age >20-years-old; without known neuropathy, dia-
betes, or chronic medical condition; BMI< 25) were tested using
Sudoscan™ to determine population normative values. The results
of this study are depicted inTable 4 and indicate the following: (1)
there is almost no drop-off in normal sudomotor function from
age 21 to 80; (2) results are not significantly different between the
sexes; and (3) a threshold of 60µS for hands and feet does not
result in a significant number of false positives (healthy subjects
being diagnosed with dysautonomia). Only in the eighth decade,
do mean ESC values decrease slightly (eighth vs. third decade
feet ESC: 75.5 9.3 vs. 83.9 5.8µS for women, respectively;
76.0 9.4 vs. 81.7 7.6µS for men, respectively).
Cohorts of diabetic patients, both with and without DPN, then
underwent ESC testing by Gin and Yajnik (37, 38); these stud-
ies indicated that a threshold of 60µS clearly separated normal
(“green” zone) from abnormal (“yellow” and “red” zones) sudo-
motor function for both the hands and feet. A second thresh-
old of 40µS denoted the level below which sudomotor function
was severely impaired (“red” zone) and correlated closely with
advanced peripheral neuropathy and attendant complications,
e.g., foot ulceration (34, 37, 38).
Three critical studies were then completed in the US (9, 34, 43)
and led to further refinement of ESC thresholds by comparing
ESC scores against multiple validated DPN tools. Results of these
studies demonstrated that: (1) the initial 40 and 60µS thresholds
best applied to Asian populations; (2) optimal sensitivity of ESC
testing in Caucasians required raising the foot ESC threshold to
70µS; and (3) African Americans had unique sudomotor physi-
ology requiring specific ESC thresholds for both hands and feet.
Though threshold refinement by ethnic background has not yet
been clinically validated for all populations, using the adjustments
depicted in Table 5 below is already allowing much stronger
accuracy of ESC result interpretation and clinically meaningful
information for the physician.
Reproducibility testing was performed under various stress
scenarios as well as normal conditions.
Effect of Chronic Disease
Electrochemical skin conductance measurements were assessed
twice on the same day in patients with at least one cardiovascular
risk and in patients with diabetes. Results were compared using a
Bland–Altman plot. The coefficient of variation was 7% in hands
and 5% in feet in patients with cardiovascular risk and 15% in
hands and 7% in feet in patients with diabetes in whom the coef-
ficient of variation for glycemia between the two measurements
was 32%.
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TABLE 2 | Spearman’s ρ ranked correlations of feet ESC with clinical,
somatic, and autonomic measures of neuropathy in 48 patients with type 2
diabetes (34).
Feet ESC Spearman ρ p-Value#
CLINICAL NEUROPATHY SCORES
DM duration Feet ESC  0:4904 0:0005
Neurologic symptom
score (NSS)
Feet ESC  0:4437 0:0016
Sensory score Feet ESC  0:6313 <0:0001
Motor score Feet ESC  0:5499 <0:0001
Total neuropathy score
(TNS)
Feet ESC  0:5851 <0:0001
Total NIS-LL motor Feet ESC  0:6687 <0:0001
Total NIS-LL sensory Feet ESC  0:6672 <0:0001
Total NIS-LL score Feet ESC  0:6160 <0:0001
AUTONOMIC FUNCTION MEASURES (QAFTs)a
Expiration/inspiration ratio
(E/I)
Feet ESC 0:4858 0:0005
Valsalva ratio Feet ESC 0:3182 0:0275
Deep breathing total
spectral power (TSP)
Feet ESC 0:4745 0:0008
Deep breathing sdNN Feet ESC 0:4252 0:0029
Deep breathing rmsSD Feet ESC 0:3778 0:0088
Valsalva TSP Feet ESC 0:4320 0:0024
Valsalva sdNN Feet ESC 0:3708 0:0103
Valsalva rmsSD Feet ESC 0:3026 0:0387
QUANTITATIVE SENSORY TESTING (QSTs)
Great toe vibration
detection
Feet ESC  0:5003 0:0004
Great toe pressure
(monofilament)
Feet ESC  0:6250 <0:0001
Great toe cold perception Feet ESC  0:4625 0:0012
Great toe warm
perception
Feet ESC  0:4857 0:0006
PAIN SCORES (NRS)
Great toe symptomatic
pain
Feet ESC  0:4397 0:0022
Great toe mechanical pain Feet ESC  0:3508 0:0168
NERVE CONDUCTION STUDIES (NCS)
Peroneal ankle amplitude
(Amp)
Feet ESC 0:4889 0:0005
Peroneal below fibula Amp Feet ESC 0:5867 <0:0001
Peroneal below fibula
conduction velocity (CV)
Feet ESC 0:4724 0:0008
Peroneal above fibula Amp Feet ESC 0:5496 <0:0001
Peroneal above fibula CV Feet ESC 0:4381 0:0021
Sural Amp Feet ESC 0:5234 0:0043
Sural CV Feet ESC 0:5503 0:0024
LABORATORY VARIABLES
Urine albumin/creatinine
ratio
Feet ESC  0:3724 0:0196
aData are log-transformed.
#Spearman’s ρ rank test was applied.
DM, diabetes mellitus; ESC, electrochemical skin conductance; NIS-LL, neuropathy
impairment score of lower legs; NRS, numeric rating score; rmsSD, root mean square
of the difference of successive R–R intervals; sdnn, sample difference of the beat to beat
(NN) variability.
Effect of Glycaemia
As this technology is frequently applied to pre-diabetic or diabetic
patients with potentially high glycemic variations, ESC measure-
ments were performed twice in 12 patients, once when blood
FIGURE 3 | Receiver operating characteristics (ROC) curves for feet
ESC and skin biopsy using abnormal Utah Early Neuropathy Score
(UENS) as the gold standard. Area under the curve (AUC) for ESC feet and
intraepidermal nerve fiber density (IENFD) were similar (0.761, 0.752,
respectively) (9).
glucose levels were 325mg/dL and once when normoglycemic.
The coefficient of variation between the two sets of measurements
from a Bland–Altman plot was 10% in the feet. This is not unex-
pected as hyperglycemia induces a state of hyperosmotic dehy-
dration. In hyperosmolar hyperglycemic non-ketotic syndrome,
there is an absence of sweating in an attempt to conserve water,
probably with diversion of blood from cutaneous microvascular
beds. It may be that the ESC test, despite supra-physiological
stimulation of the sweat glands, is unable to overcome the body’s
conservationmechanism, leading to changes in ESC results during
hyperglycemia. Just as the stomach is paralyzed by hyperglycemia
and gastric emptying should only be measured when blood glu-
cose levels are near normal (<250mg/dL) so should sudorimetry
strive to be examined only when the blood glucose is near normal.
Effect of Exercise
As exercise could influence sweat function, measurements were
taken before and after an ergonomic bicycle exercise test at a level
of 87% of maximum heart rate. ESC before and after measure-
ments had a coefficient of variation of 4% in the feet and 8% in
the hands.
Effect of the Device
Three measurements were performed in 21 patients using three
different devices. There was no significant difference between the
three measurements, and the paired Spearman test evidenced a
coefficient of correlation higher than 0.96 for each comparison
(p< 0.0001) (44).
Sudomotor Function and Aging
It is now well accepted that important changes to the autonomic
nervous system occur with aging, leading not only to increased
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TABLE 3 | Feet ESC diagnostic accuracy vs. established clinical tools.
Study Diagnostic variable Comparison Sensitivity (%) Specificity (%) PPV (%) NPV (%)
Casellini (34) DPN NIS-LL 78 92 74 93
Smith (9) Distal symmetric polyneuropathy UENS 77 67 59 83
Yajnik (37) DPN VPT 73 62 N/A N/A
Eranki (41) DPN VPT 82 55 N/A N/A
Calvet (39) CAN – diabetes CARTs 83 63 N/A N/A
Ozaki (42) Diabetic kidney disease eGFR, ACR 94 78 81 93
ACR, albumin creatinine ratio; CAN, cardiac autonomic neuropathy; CARTs, cardiac autonomic reflex tests; DPN, diabetic peripheral neuropathy; eGFR, estimated glomerular filtration
rate; NIS-LL, Neuropathy Impairment Score – Lower Limbs; PPV, positive predictive value; NPV, negative predictive value; UENS, Utah Early Neuropathy Score; VPT, vibration perception
threshold.
TABLE 4 | Effects of age and gender on ESC measurements in 609 normal subjects.
Age (years)a
Overall 21–30 31–40 41–50 51–60 61–70 71–80
FEMALE
ESC hands (n= 432) (n= 29) (n= 73) (n= 136) (n=143) (n= 28) (n= 23)
MeanSD 74.08.7 74.79.6 75.98.8 74.08.4 73.88.3 71.110.1 71.09.6
Median 75.0 75.0 77.0 74.5 75.0 70.3 71.5
80th percentile interval 61.5–85.0 62.6–86.2 62.6–87.0 62.0–85.0 62.0–85.0 58.9–83.6 55.9–81.4
ESC feet
MeanSD 82.85.8 83.95.8 84.24.8 83.15.2 82.75.6 82.24.2 75.59.3
Median 83.5 84.5 85.0 84.5 83.0 83.0 79.0
80th percentile interval 76.0–89.0 79.1–90.0 77.1–89.5 76.5–89.0 75.5–89.5 76.7–86.5 65.1–86.7
MALE
ESC hands (n= 177) (n= 46) (n= 30) (n= 33) (n= 42) (n= 10) (n= 16)
MeanSD 74.99.6 76.010.1 77.46.6 75.210.7 75.87.7 72.311.6 66.210.0
Median 76.5 77.5 78.3 78.0 76.3 75.0 68.0
80th percentile interval 62.5–86.5 63.0–87.5 69.1–85.6 61.1–87.9 66.7–86.4 56.1–85.6 52.5–78.3
ESC feet
MeanSD 81.57.0 81.77.6 81.25.6 81.07.1 84.05.7 81.54.4 76.09.4
Median 82.5 82.5 81.0 83.0 84.5 81.8 79.3
80th percentile interval 73.0–89.5 73.8–90.5 75.0–88.2 71.3–89.3 76.1–90.0 76.7–86.2 67.5–83.5
a Internal data provided by Impeto Medical, Inc.
TABLE 5 | Electrochemical skin conductance (ESC) zones for normal sudomotor function (green), moderate sudomotor dysfunction (yellow), and severe
sudomotor dysfunction (red) as defined by racial background.
Race Hands ESC
red zone
Hands ESC
yellow zone
Hands ESC
green zone
Feet ESC
red zone
Feet ESC
yellow zone
Feet ESC
green zone
Caucasian 0–40 40–60 60–100 0–50 50–70 70–100
African-American Ancestry 0–30 30–50 50–100 0–40 40–60 60–100
Asian, Indian 0–40 40–60 60–100 0–40 40–60 60–100
All numeric values in micoSiemens (µS).
Data from Casellini, Gordon Smith, and Freedman (9, 34, 43).
morbidity and mortality but also complicating the therapeutic
care of comorbidities of elderly patients, e.g., the use of sympa-
tholytic drugs and diuretics for hypertension or the optimization
of glucose control for diabetes (45). Extensive research indicates
that both sympathetic and parasympathetic dysfunction occur
with age, with tonic vagal modulation decreasing and a relative
or absolute increase in sympathetic tone (46, 47). Schmidt notes
that neurons in the aging sympathetic ganglia are mostly intact,
whereas dendrites, axons, and synapses can be severely abnormal
and very likely contribute to faulty signaling (45).
It must be noted, however, that the degree of autonomic dys-
function in the elderly can be highly dependent on fitness level,
obesity, and to a lesser extent gender (48–50). Our data on ESC
only show a reduction in this function in the 8th decade (Table 4).
Some studies have indicated decreased sweat volumes on the
dorsum of the hands and feet with aging (51), while Low found
significant decreases in quantitative sudomotor axon reflex test
(QSART) only in the lower extremities (52). In an earlier publi-
cation, Low had saliently concluded that age-related changes of
the ANS vary with “the system tested, the site examined, and
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the particular test used” (53). We contend that ESC reflects not
only sweating but somatic neurologic function which declines
with age (54).
Sudoscan™ examines the palms and soles, and measures an
electrochemical response from the skin rather than a sweat volume
or latency of response. As such, ESC results across ages 21–80 in
healthy individuals have been found to remain fairly constant, and
certainly permit use of a uniform set of diagnostic thresholds. This
in turn allows identification of sudomotor dysfunction in older
adults equally as easily as in younger ones (Table 4).
ESC as a Tool to Measure Progression
and Regression of Disease
One of the most difficult and frustrating tasks in peripheral neu-
ropathy has been to measure disease progression and response
to therapeutic intervention with an easy, objective, and accu-
rate tool. Knowing that salvaging large nerve fibers is practically
impossible, the Holy Grail is to detect early nerve damage –
perhaps before metabolic parameters indicate any disease – and
measure response or lack thereof accurately and quickly, allowing
for treatment modification. Several research studies have now
demonstrated that ESC may be a clinically meaningful tool in
measuring neuropathy progression and regression.
In a cohort of 52 type 1 and 115 type 2 diabetic patients
followed for 1 year, Calvet and colleagues (39) showed that a
decrease in hand and foot ESC was observed in Type 2 patients
treated without insulin, while a significant increase was observed
in patients receiving insulin ( 3.8 9.7 vs. 1.0 9.7µS, p= 0.02
for the hands and  2.2 7.5 vs. 4.1 8.8µS, p< 0.001 for the
feet). Type 1 patients, all on insulin, had a non-significant increase
in their feet ESC as well (1.0 7.2µS). During this period, none
of the cohorts (insulin/no insulin) had any significant change
in their glycemic control which would signal a need for thera-
peutic adjustment (delta HbA1c 0.07 0.60% and 0.13 0.87%,
respectively); yet, clearly the no insulin group was experiencing
ongoing peripheral nerve loss. This lack of relationship with
glycemic control argues in favor of an effect of insulin per se
on Cl  ion transport. Insulin is known to enhance the activ-
ity of Na+–K+–2Cl  co-transporter (NKCC). Recently, Sun
and colleagues demonstrated that insulin treatment remarkably
enhanced the forskolin-stimulated Cl  secretion in epithelial A6
cells, which was associated with an increase in apical Cl  con-
ductance by upregulating mRNA expression of both CFTR and
NKCC (55). It would be of interest to examine the direct effects of
euglycemic insulin administration as well as insulinotropic drugs
on ESC quantification of Cl transport. Furthermore, sudorime-
try may well prove useful in the evaluation of hyperinsulinemic
insulin resistant states.
Conversely, Raisanen and colleagues (56) demonstrated that
therapeutic intervention could improve small fiber function, and
is easily measured using ESC. Residents of Tornio, Finland, who
were at high cardiometabolic risk (BMI >35 kg/m2, very low
VO2max, diabetes, or heart disease), completed a supervised
health promotion program for 12months. Among 154 female
participants with the lowest fitness level at baseline, those per-
forming the highest level of weekly activity showed the greatest
improvement in ESC scores, which was more pronounced than
the changes in weight, waist circumference, or VO2max (Table 6).
Raisanen’s results confirm previous findings by Smith et al. (57)
that small C-fibers damaged by metabolic stress can recover from
simple lifestyle interventions lending further support to the notion
that sudorimetry detects small somatic nerve fiber function that
do not necessarily innervate sweat glands.
These studies indicate that ESC may provide information on
the metabolic health of a patient, in particular on their small
nerves, which may not otherwise be known to or measurable
by the physician. Initial ESC results may be used to alter man-
agement and repeat testing after intervention may accurately
measure whether the treatment is effective or if further changes
are necessary. Significantly, the test is easy and precise enough
to be clinically useful and meaningful for everyday outpatient
practices.
One often neglected aspect of peripheral neuropathy is its
impact on the patient’s quality of life. Excellent tools such as
the Norfolk Quality of Life-Diabetic Neuropathy (QOL-DN)
have been developed to measure the patient’s experience of dia-
betic neuropathy. The nerve fiber-specific domains of QOL-
DN, in particular, have been shown to correlate with objective
measures of nerve function (58–60). QOL-DN has also been
shown to be a reliable indicator of the impact on QOL of
symptomatic peripheral neuropathy experienced by patients with
TABLE 6 | Change between baseline and 12-month follow-up in weight, waist, VO2max, and ESC risk score value in 154 women included in a lifestyle
intervention program (56).
Without follow-up
of training level (n= 72)
Low weekly
activitya (n= 62)
High weekly
activityb (n= 20)
p
Mean SD Mean SD Mean SD
Change in weight (kg)  0.9 3.4  1.6 4.0  3.3 4.8 NS
Change in waist (cm)  2.1 4.7  2.4 4.5  3.6 5.9 NS
Change in estimated VO2max (METs) +0.5 0.9 +0.8 0.9 +1.1 1.2 NS
Change in hand ESC (µS) +5.0 8.4 +3.0 9.4 +8.4 12.3 0.043
Change in foot ESC (µS) +5.6 8.9 +4.9 8.9 +10.8 12.8 0.024
Change in ESC risk score (%)  5.1 5.3  4.7 6.4  8.5 6.8 0.027
aLess than 150min of moderate activity and 75min of high activity.
bMore than 150min of moderate activity or 75min of high activity; moderate activity 3–7 METs; high activity >7 METs.
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FIGURE 4 | (A) ESC report dated October 19, 2012. (B) ESC report dated March 6, 2014.
V30M Transthyretin Familial Amyloid Polyneuropathy (TTR-
FAP) (61) In the Tafamadis study, Coelho and colleagues (62, 63)
demonstrated that treatment of patients with TTR-FAP was asso-
ciated with an improvement of Norfolk QOL scores of symptoms
and activities of daily living in parallel with improved NIS-LL,
supporting the notion that the QOL tool can be nerve fiber spe-
cific. Concurrently, early studies have shown that ESC is able to
clearly discriminate the degree of small nerve fiber dysfunction in
symptomatic vs. asymptomatic TTR-FAP (mean feet ESC: 42 27
vs. 81 10µS; p< 0.0001, respectively) (unpublished data). The
next obvious step would be to measure the impact that ESC and
QOL-DN together could have on disease staging andmanagement
in FAP, diabetes mellitus, and other small fiber neuropathies.
Conclusion
Small nerve fibers are starting to be recognized as valuable neu-
ronal structures in the investigation of neuropathic diseases. They
are thin, poorly myelinated, or unmyelinated, and therefore prone
to destruction early in many pathological processes and often
symptomatically debilitating. Indeed, the earliest changes appear
to occur in the lower back, forearm, and thenar eminence as
shown using Contact Heat Evoked Potential (CHEPS) (64), chal-
lenging the dogma that neuropathy is a distal to proximal disorder.
Small nerves can be assessed objectively, and recognition of early
dysfunction can allow intervention, treatment, and potentially
cure. Though skin biopsy with IENFD is currently recognized as
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FIGURE 5 | (A) ESC report dated February 19, 2013. (B) ESC report dated March 6, 2014.
the gold standard in the evaluation of small fibers, sudorimetry
technology has evolved dramatically; appears to be a rapid, non-
invasive, robust, and accurate biomarker for small fibers; and
can easily be integrated into clinical practice. Disease detection,
progression, and response to therapy have been shown to be
measurable with ESC, and it may eventually assist the physician
in monitoring more challenging disorders like CIDP. To allow for
global evaluation of sudomotor function, however, the technology
would need to be expanded in order to obtain information on
dermatomes across the entire body.
Case Vignettes on the Clinical Utility of
Sudorimetry
Prior studies demonstrate that ESC technology is able to rapidly
and precisely measure the effects of a therapeutic intervention;
furthermore, individual patient examples are suggesting similar
results. Below are two patients whose small nerve fiber function
was uniquely measurable by sudorimetry.
Vignette 1
The patient is a 47-year-old woman with well-controlled type 1
diabetes (HbA1c 6.4–7.5%) and 8+ years of painful diabetic neu-
ropathy and gastroparesis. ESC measurements (Figure 4A) and
cardiac autonomic functions were abnormal: heart rate variability
response to expiration/inspiration (E/I), Valsalva maneuver, and
the ratio of the RR interval for the 30th to the 15th beat upon
standing were 1.05, 1.10, and 1.06, respectively. Gastroparesis
was confirmed by a gastric emptying study and required a com-
bination of psyllium fiber, metoclopramide, and erythromycin
EES. Alpha lipoic acid (ALA) 600mg po bid was prescribed.
Ten months later, the patient returned with normalized ESC
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results (Figure 4B), complete resolution of the gastroparesis, but
unchanged peripheral neuropathy symptoms, autonomic func-
tions (E/I, Valsalva, and 30:15 ratios 1.10, 1.08, 1.08, respectively),
and HbA1c.
Past research has suggested that ALA may benefit diabetic
neuropathy, but objective quantification of its therapeutic effects
has been difficult (65). The authors of a 2012 meta-analysis of
ALA trials confirmed that 3weeks of intravenous ALA results in
significant and clinically relevant reductions in neuropathic pain
(66) but declared that it was unclear if significant improvements
measured for oral ALA were clinically relevant. Mijnhout et al.,
though, based their conclusions on the evolution of a single out-
come measure, namely a 30% change in Total Symptom Score
(TSS). The NATHAN 1 study, comparing 600mg daily oral ALA
vs. placebo, did notmeet its primary endpoint (NIS-LL plus 7 neu-
rophysiologic tests), despite 4 years of follow-up. However, Neu-
ropathy Impairment Score, NIS-LL, and Neuropathy Symptoms
and Change (NSC) score improved with ALA (67). NATHAN 1
firmly demonstrated that diabetic neuropathy, especially nerve
conduction deficits, progresses quite slowly and that it may be
more sensible to measure improvements in the treatment arm of
a study rather than deficit progression in the placebo arm. ESC
measurement was able to demonstrate improvements in small
fibers with use of ALA in this patient; the ESC normalization
correlated with resolution of her gastroparesis and opens the door
to further investigate ESC’s utility in measuring pharmacological
intervention in autonomic neuropathy.
Vignette 2
The patient is a 50-year-old male with type 2 diabetes and a BMI
of 30. He had been treated with metformin for several years and
was optimally controlled. He denied any symptom of neuropathy;
yet, ESCmeasurements demonstrated moderate sudomotor func-
tion loss (Figure 5A). A vitamin B12 level drawn that day was
low (<150 pg/mL). He was started on vitamin B12 replacement
and continued metformin. A repeat ESC 3months later showed
recovery of feet ESC scores (Figure 5B).
It has now been established that vitamin B12 threshold levels
leading to impairment of nerve function is around 260 pmol/L
(70 pg/ml) as shown in the Health ABC study (68). This case
illustrates not only ESC’s ability to measure therapeutic response,
but also its diagnostic capacity to detect a (possibly iatrogenic)
neuropathy prior to symptomatology and identity candidates on
metformin for B12 replacement. Fonseca and colleagues were
unable to show that 24weeks of treatment with a combination
of methylcobalamin, methylfolate, and pyridoxal phosphate could
alter vibration detection despite improving symptoms of neuropa-
thy as well as quality of life (69, 70). Their study findings support
the possible role of an objective measure like ESC in this clinical
setting.
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